1.Boezio, A.A.,Copeland, K.W.,Rex, K., et al. Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a potent and selective inhibitor of MET with high unbound target coverage and robust in vivo antitumor activity. J. Med. Chem. 59(6), 2328-2342 (2016).
2.Hughes, P.E.,Rex, K.,Caenepeel, S., et al. In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models. Mol. Cancer Ther. 15(7), 1568-1579 (2016).
3.Caenepeel, S.,Cooke, K.,Wadsworth, S., et al. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget Epub ahead of print, (2017).
|
